Pudu Robotics Announces Newly Released Puductor2 to Improve Public Health Safety
Pudo Robotics announced today the release of Puductor2, a technology-based, anti-pandemic robot. This newly designed intelligent robot has two disinfection modes of ultra-dry mist and UV-C ultraviolet ray, featuring large domain of walk, long detection distance, high positioning accuracy, and stronger environmental adaptability. Puductor2 further expands its scope of application while enhancing its disinfection and killing ability, to include such locations as government halls, schools, medical institutions, waiting rooms, airports, subways, banks and other public places.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201128005104/en/
(Photo: Business Wire)
According to the BBC news, the coronavirus bounced back in late October in European countries. In 10 days, the cumulative confirmed cases in the 53 European member states of the World Health Organization (WHO) have soared from 6 million to more than 7 million.
Against the backdrop of the pandemic, European countries have adopted methods such as limiting the number of gatherings, early curfews, and lockdowns to fight this new battle without affecting the economy. In fact, all fail to keep the virus under better control. Some experts suggest that Europe and the United States can learn and follow China's anti-pandemic approaches, that is, technology-based anti-pandemic measures. For example, in the hospitals and quarantine points in Wuhan, China, where witnessed the most severe virus in early 2020, intelligent robots were used to disinfect the pandemic areas and deliver daily medical supplies, such as delivering food, water, medicine and other necessities to patients. Under serious shortage of medical staff and medical supplies, the participation of robots in the fight against the pandemic will not only improve work efficiency and reduce the loss of medical supplies, but also substantially reduce contact between personnel, thus effectively slowing the spread of the pandemic.
Among technical anti-pandemic robots, the most common one is "Pudubot", a product from the Chinese company - Pudu Robotics. It is understood that Pudu Robotics, headquartered in Shenzhen, China's tech capital, serves as a national high-tech enterprise home to R&D, design, production and sales of commercial service robots. Its distribution service robots "Pudubot", "Bellabot", and "Holabot" have been widely introduced in the catering industry, and cooperation with domestic catering giants such as Haidilao have been successively reached. In order to support the fight against the pandemic, the ultra-dry mist disinfection robot Puductor developed and produced by Pudu Robotics is also widely used in hotels, restaurants, airports, medical institutions, government halls, etc., around the world for disinfection. It is reported that Puductor adopts the ultra-dry mist disinfection technology, which can capture harmful microorganisms in the air and quickly disinfect and kill bacteria and viruses, such as the currently raging COVID-19, with a sterilizing rate of 99.99%.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201128005104/en/
Contact information
Hilary Lee
Tel:+86 400-0826-660
E-mail:global_sales@pudutech.com
https://pudurobotics.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CORRECTING and REPLACING PHOTO Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 21:23:00 EEST | Press release
Please replace the photo with the accompanying corrected photo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. The release reads: DECODE THE FUTURE OF AI AND CUSTOMER EXPERIENCE AT ELEVATE'25 DIGITAL INNOVATION SUMMIT With keynotes from Google Cloud and an independent research firm, Elevate’25 will provide actionable strategies to harness the power of AI and create exceptional experiences for today's mobile-first consumer As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. Taking place on October 15, 2025, at the i
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release
Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release
AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by
illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release
illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom